Objective:

To educate patients about geographic atrophy (GA) and their treatment options, including FDA-approved intravitreal complement inhibitors, while addressing the challenges in patient selection and clinic workload.

Key Findings:

• Patients often feel overwhelmed by information regarding GA and treatment options.
• FDA-approved therapies can slow disease progression but do not restore lost vision.
• Involving family in discussions can aid patient understanding and decision-making.
• Family involvement is crucial for patients to process information and make informed choices.

Interpretation:

The editorial emphasizes the importance of patient education, shared decision-making, and ongoing communication in managing GA, highlighting the need for support throughout the treatment process.

Limitations:

• Some specialists may hesitate to offer treatment due to clinic workload, impacting patient access to care.
• Not all patients may be suitable candidates for treatment.

Conclusion:

Emerging treatments for GA provide hope for improved patient outcomes, and current therapies represent a significant advancement for previously untreatable conditions.